Premium Nahrungsergänzungsmittel | artgerecht

Phlegmasia coerulea dolens – Causes and Treatment

Phlegmasia coerulea dolens is a rare, life-threatening form of massive deep vein thrombosis causing severe limb swelling, intense pain, and a characteristic blue-purple skin discoloration.

Regular tips about health Regular tips about health

Things worth knowing about "Phlegmasia coerulea dolens"

Phlegmasia coerulea dolens is a rare, life-threatening form of massive deep vein thrombosis causing severe limb swelling, intense pain, and a characteristic blue-purple skin discoloration.

What is Phlegmasia coerulea dolens?

Phlegmasia coerulea dolens (Latin: painful blue inflammation) is a severe, life-threatening complication of massive deep vein thrombosis (DVT). It occurs when nearly all of the deep veins of an extremity -- most commonly the leg -- become occluded by thrombus, causing critical venous outflow obstruction. This results in extreme swelling, intense pain, and a characteristic blue-purple (cyanotic) discoloration of the skin. Without rapid treatment, the condition can progress to tissue death (gangrene), limb loss, and in severe cases, death.

Causes and Risk Factors

The condition arises from an extensive thrombosis that blocks most of the deep venous system of a limb, nearly completely interrupting venous blood return. Common causes and risk factors include:

Advanced malignancies (especially pancreatic, lung, and colorectal cancer)
Prolonged immobility or bed rest
Severe heart failure or circulatory shock
Hypercoagulable states (e.g., antiphospholipid syndrome, Factor V Leiden mutation)
Major surgery, particularly pelvic or hip procedures
Pregnancy and the postpartum period
Severe dehydration
History of prior deep vein thrombosis

Symptoms

The clinical presentation of phlegmasia coerulea dolens is distinctive and rapidly progressive:

Massive swelling of the entire affected extremity
Severe, burning pain in the affected leg or arm
Blue-purple skin discoloration (cyanosis) due to venous engorgement
Skin tension and firmness
Weakening or complete absence of arterial pulses in advanced stages
Coldness and numbness of the affected limb
In late stages: blistering, skin necrosis, and gangrene
Systemic signs including hypotension, circulatory shock, and altered consciousness in severe cases

It is important to distinguish this condition from its milder precursor, phlegmasia alba dolens (painful white edema), in which venous obstruction is incomplete and the skin appears pale rather than cyanotic.

Diagnosis

Diagnosis is primarily clinical and confirmed by imaging studies:

Duplex ultrasonography: The first-line imaging modality to confirm thrombosis and assess venous flow
CT venography or MR venography: For precise mapping of thrombosis extent and planning of interventional procedures
D-dimer: Markedly elevated in the blood, though non-specific
Laboratory investigations: Complete blood count, coagulation parameters, renal and hepatic function, and workup for underlying conditions (e.g., tumor markers)

Treatment

Phlegmasia coerulea dolens is a medical emergency requiring immediate intensive care. The treatment goals are to prevent gangrene, pulmonary embolism, and death.

Conservative Treatment

Immediate anticoagulation with unfractionated heparin (UFH) as a first-line measure to prevent further clot propagation
Elevation of the affected extremity to promote venous drainage
Intensive care monitoring and hemodynamic stabilization
Adequate pain management and fluid resuscitation

Interventional and Surgical Treatment

Catheter-directed thrombolysis (CDT): Dissolution of the thrombus through local delivery of thrombolytic agents (e.g., alteplase) via catheter -- the preferred approach in suitable patients
Percutaneous mechanical thrombectomy: Mechanical removal of the thrombus using catheter-based devices
Surgical thrombectomy: Operative thrombus removal, especially when interventional approaches are unavailable or contraindicated
Fasciotomy: Surgical decompression when compartment syndrome is imminent
Inferior vena cava filter placement: Considered in patients at high risk of pulmonary embolism who cannot receive thrombolytic therapy

Long-Term Management

Following acute treatment, long-term oral anticoagulation is indicated, with the duration determined by the underlying cause. In patients with active malignancy, low-molecular-weight heparin or direct oral anticoagulants (DOACs) are preferred. Identification and management of the underlying cause is essential.

Prognosis

The prognosis is serious: without prompt treatment, patients face a high risk of limb amputation, pulmonary embolism, and death. With timely and aggressive therapy, most limbs can be salvaged, but outcomes depend heavily on disease severity and the presence of comorbidities. Reported mortality rates range from 20 to 40% in the literature.

References

Chinsakchai K. et al. - Trends in Management of Phlegmasia Cerulea Dolens. Vascular and Endovascular Surgery, 2011.
Henke PK. - Contemporary management of acute limb ischemia: factors associated with amputation and in-hospital mortality. Annals of Vascular Surgery, 2007.
Kearon C. et al. - Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest, 2016.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.